research Botulinum toxin type A for the management of hidradenitis suppurativa.
Botulinum toxin type A may help treat hidradenitis suppurativa.
Search
for
Sort by
Research
810-840 / 1000+ resultsresearch Factors Related to Hair Antiretroviral Concentration: A Systematic Review of Global Literature
Hair antiretroviral concentration is affected by hair type, segment position, housing, drug use, sexual behavior, kidney function, and genetics.
research Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism
research 436 Allergic contact dermatitis stimulates hair follicle stem cells via macrophage-mediated regulation
Allergic contact dermatitis may promote hair growth by activating hair follicle stem cells.
research Women Also Use 5α-Reductase Inhibitors—Reply
Women also use 5α-reductase inhibitors, and their effects differ from men.
research Protective role of hesperidin in finasteride-induced testicular toxicity in adult male Wistar rats: Insights into oxidative stress, apoptosis, and ultrastructure of seminiferous tubules
Hesperidin helps protect against testicular damage caused by finasteride.
research Understanding the evolving treatment landscape of hidradenitis suppurativa: An analysis of All of Us
Improving access to hidradenitis suppurativa care can reduce social disparities.
research Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data
Antiandrogen therapy for hidradenitis suppurativa lacks strong evidence and needs more research.
research MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
research Pharmacological Role and Clinical Applications of 5α-Reductase Inhibitors-Review Article for Pharmacists and Healthcare Professionals
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
research Baricitinib Induced Hypoglycemic Seizures in a Patient with Hair Loss and Type I Diabetes Mellitus: A Case Report
Baricitinib may cause low blood sugar in some patients, so careful monitoring is needed.
research High-performance liquid chromatographic determination of the enantiomers of the benzoquinolinone LY 191704, a human type 1 5α-reductase inhibitor, in plasma
Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
research Pharmacological inhibition of 5α-reductase in androgenetic alopecia: a comparative narrative review of finasteride and dutasteride, with attention to responder heterogeneity and female pattern hair loss
Finasteride and dutasteride are the most evidence-supported pharmacological treatments for androgenetic alopecia (AGA) in both men and women. Finasteride 1 mg/day reduces serum DHT by about 70%, while dutasteride 0.5 mg/day achieves approximately 90% suppression, with dutasteride showing slightly greater hair count gains. A pivotal trial found dutasteride 2.5 mg superior to finasteride 5 mg/day, but the 0.5 mg dose is standard due to its efficacy and lower systemic exposure. Genetic factors, particularly androgen receptor variations, significantly influence treatment response. In women, higher doses of finasteride and variable doses of dutasteride are effective, especially in postmenopausal and some premenopausal groups. The choice between these drugs involves balancing DHT suppression, drug half-life, and tolerability, with genetic modifiers being an important area for future research.
research Pharmacological inhibition of 5α-reductase in androgenetic alopecia: a comparative narrative review of finasteride and dutasteride, with attention to responder heterogeneity and female pattern hair loss
Finasteride and dutasteride are the most evidence-supported pharmacological treatments for androgenetic alopecia (AGA) in both men and women. Finasteride 1 mg/day reduces serum DHT by about 70%, while dutasteride 0.5 mg/day achieves approximately 90% suppression, with dutasteride showing slightly greater hair count gains. A pivotal trial found dutasteride 2.5 mg superior to finasteride 5 mg/day, but the 0.5 mg dose is standard due to its efficacy and lower systemic exposure. Genetic factors, particularly androgen receptor variations, significantly influence treatment response. In women, higher doses of finasteride and variable doses of dutasteride are effective, especially in postmenopausal and some premenopausal groups. The choice between these drugs involves balancing DHT suppression, drug half-life, and tolerability, with genetic modifiers being an important area for future research.
research BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
research Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
Upadacitinib effectively treated severe hair loss in a child.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Actions of 5α-reductase inhibitors on the epididymis
5α-reductase inhibitors may reduce male fertility and could be used for male contraception.
research Inhibitory effect of 7DHC and BM15766 in HF organoid culture.
7DHC and BM15766 damage hair follicle structure and reduce key gene expression.
research Congenital adrenal hyperplasia
CAH is a genetic disorder affecting cortisol production and causing hormonal imbalances, with treatment and diagnosis varying by form and symptoms.
research Mechanistic synergy of hair growth promotion by the Avicennia marina extract and its active constituent (avicequinone C) in dermal papilla cells isolated from androgenic alopecia patients
Avicennia marina extract and avicequinone C can potentially promote hair growth and treat hair loss by interfering with hair loss mechanisms and boosting growth factors.
research Hormonal Treatment for Skin Androgen-Related Disorders
Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.
research Partial cicatricial alopecia after temporal filler with hyaluronic acid
Hyaluronic acid fillers can cause hair loss if used near hair.
research Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review
Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
research Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
Cardiovascular drugs can cause various skin problems, so recognizing these reactions is important.
research Clascoterone: a new topical antiandrogen agent.
Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.
research Re-Densification Effect of Pressure-Injected Peptide-Hyaluronic Acid Combination on Male Androgenic Alopecia
Injecting a peptide-hyaluronic acid mix improved hair growth in men with hair loss and was safe.
research 098 Simvastatin decreases AA-associated inflammation through effects on isoprenoid metabolites
Simvastatin reduces inflammation and promotes hair regrowth in alopecia areata.
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research Clascoterone as a novel treatment for androgenetic alopecia
Clascoterone may be a promising treatment for hair loss.